JBPHF (Jacobio Pharmaceuticals Group Co) Moat Score: 2/10 (As of Jun. 28, 2026)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.42
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Moat Score?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.42. The stock has 6 warning signs investors should review. Among 1,402 Biotechnology companies, Jacobio Pharmaceuticals Group Co ranks better than 58.06% on this metric.

Jacobio Pharmaceuticals Group Co has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Jacobio Pharmaceuticals Group Co has No Moat: Jacobio Pharmaceuticals operates in a highly competitive pharmaceutical market with limited market share and lacks significant patents or regulatory barriers. Its competitive advantages are weak and not durable.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Jacobio Pharmaceuticals Group Co might have No Moat - Very weak/transient advantages.

Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Jacobio Pharmaceuticals Group Co Moat Score Related Terms

JBPHF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jacobio Pharmaceuticals Group Co Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Moat Score falls into.


JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Jacobio Pharmaceuticals Group Co's Moat Score too high?
Jacobio Pharmaceuticals Group Co's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Jacobio Pharmaceuticals Group Co's value of 2 is 0% at this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #588 out of 1402 companies for Moat Score. This puts Jacobio Pharmaceuticals Group Co in the upper half of its industry. The industry median Moat Score is 2.00. Jacobio Pharmaceuticals Group Co's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Moat Score of 2. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.

Key valuation signals for JBPHF:

  • Moat Score: 2
  • GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
  • GF Score™: 54/100 with 6 warning signs
  • Industry Position: 0% at the Biotechnology median (#588 of 1402)

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.42
GF Value